NATIONAL UNIVERSITY CORPORATION has floated a tender for A Bictegravir Sodium Emtricitabine Tenofovir Alafenamide Fumarate (30Tablets/Vial) 420Vials, And 50 other Contracts. The project location is Japan and the tender is closing on 14 Mar 2024. The tender notice number is , while the TOT Ref Number is 95553851. Bidders can have further information about the Tender and can request the complete Tender document by Registering on the site.

Expired Tender

Procurement Summary

Country : Japan

Summary : A Bictegravir Sodium Emtricitabine Tenofovir Alafenamide Fumarate (30Tablets/Vial) 420Vials, And 50 other Contracts

Deadline : 14 Mar 2024

Other Information

Notice Type : Tender

TOT Ref.No.: 95553851

Document Ref. No. :

Competition : ICB

Financier : Self Financed

Purchaser Ownership : Public

Tender Value : Refer Document

Purchaser's Detail

Name :Login to see tender_details

Address : Login to see tender_details

Email : Login to see tender_details

Login to see details

Tender Details

A Bictegravir sodium Emtricitabine Tenofovir alafenamide fumarate (30tablets/vial) 420vials, and 50 other contracts
Classification :
0004 Medical & Pharmaceutical Products
Summay of Notice :
⑴ Official in charge of disbursement of the procuring entity : Tatsuo Ushiki, President, National University Corporation Niigata University
⑵ Classification of the products to be procured : 4
⑶ Nature and quantity of the products to be purchased :
A Bictegravir sodium Emtricitabine Tenofovir alafenamide fumarate (30tablets/vial) 420vials
B Letermovir (240㎎ 14tablets/case) 300 cases
C Olaparib (100㎎ 56tablets/case) 140 cases
D Olaparib (150㎎ 56tablets/case) 420 cases
E Aflibercept (Genetical Recombination) (2㎎ 0.05mL/syringe) 480syringes
F Vutrisiran Sodium Kit (25㎎ 0.5mL/syringe) 4syringes
G Tocilizumab (Genetical Recombination) (200㎎ 10mL/vial) 1, 320vials
H Tocilizumab (Genetical Recombination) (162㎎ 0.9mL/kit) 1, 080cases
I Paclitaxel (100㎎/vial) 1, 300vials
J Cetuximab (Genetical Recombination) (100㎎ 20mL/vial) 1, 350vials
K Bevacizumab (Genetical Recombination) (100㎎ 4mL/vial) 870vials
L Bevacizumab (Genetical Recombination) (400㎎ 16mL/vial) 1, 100vials
M Durvalumab (Genetical Recombination) (120㎎ 2.4mL/vial) 460vials
N Durvalumab (Genetical Recombination) (500㎎ 10mL/vial) 450vials
O Canakinumab (Genetical Recombination) (150㎎ 1mL/vial) 30vials
P Nivolumab (Genetical Recombination) (100㎎ 10mL/vial) 210vials
Q Abatacept (Genetical Recombination) (250㎎/vial) 500vials
...

Documents

 Tender Notice